Improvement of MS has followed infusion of autologous EBV-specific CD8 T cells in some patients but not others, suggesting that there may be qualitative differences in EBV-specific CD8 T cell responses that need to be better understood (4). This evidence concerns the gene CD8A and myeloid sarcoma.